• Login
    View Item 
    •   Home
    • iBEST Institute of Biomedical and Environmental Science and Technology - to April 2016
    • Biomedicine and Nutrition Research Group
    • View Item
    •   Home
    • iBEST Institute of Biomedical and Environmental Science and Technology - to April 2016
    • Biomedicine and Nutrition Research Group
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UOBREPCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournalDepartmentThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournalDepartment

    My Account

    LoginRegister

    About

    AboutLearning ResourcesResearch Graduate SchoolResearch InstitutesUniversity Website

    Statistics

    Display statistics

    Vaccination against myeloid leukaemias using newly defined antigens

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Hofmann, Susanne
    Khan, Ghazala
    Boncheva, Viktoriya Bogdanova
    Greiner, Jochen
    Guinn, Barbara-Ann
    Issue Date
    2014
    Subjects
    myeloid leukaemia
    vaccination
    antigens
    
    Metadata
    Show full item record
    Abstract
    First complete remission rates are high in patients with acute myeloid leukaemia (AML), with some variation depending on the presence of specific cytogenetic and molecular aberrations. However, the remission is often not long lasting and relapse occurs after standard chemotherapy within two years. Besides chemotherapy, non-specific immunotherapy in the form of allogeneic haematopoietic stem cell transplantation (HSCT) is an integral part of consolidation and salvage therapy in the treatment of AML. A large number of leukaemia-associated antigens (LAAs) that can act as potential targets for specific immunotherapy have been identified, and the number is still increasing. To date, several of these antigens are being utilized in clinical vaccination trials, either as active specific immunotherapy in form of peptide vaccination or as passive specific immunotherapy as adoptive cell therapies. This chapter reviews the role of newly defined LAAs as well as the results of already performed clinical vaccination trials with known LAAs.
    Citation
    Hofmann, S., Khan, G., Boncheva, V., Greiner, J. & Guinn, B.A. (2014) 'Vaccination against myeloid leukaemias using newly defined antigens'. In Rees, R (Ed) 'Cancer Immunology Immunotherapy'. Oxford University Press.
    Publisher
    Oxford University Press
    URI
    http://hdl.handle.net/10547/578856
    DOI
    10.1093/med/9780199676866.001.0001
    Additional Links
    http://oxfordmedicine.com/view/10.1093/med/9780199676866.001.0001/med-9780199676866-chapter-19
    Type
    Book chapter
    Language
    en
    ISBN
    9780199676866
    ae974a485f413a2113503eed53cd6c53
    10.1093/med/9780199676866.001.0001
    Scopus Count
    Collections
    Biomedicine and Nutrition Research Group

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.